Anne Thiebaut-Bertrand

Anne Thiebaut-Bertrand

Auto-generated profile, based on publicly available information

Anne Thiebaut-Bertrand

CHU Grenoble, Grenoble cedex 09, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2017 in Blood
Verified
Journal Article
Closed access
PDF file
RMReid W. Merryman
Reid W. Merryman
HKHaesook T. Kim
Haesook T. Kim
PZPier Luigi Zinzani
Pier Luigi Zinzani
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
SAStephen M. Ansell
Stephen M. Ansell
PAPhilippe Armand
Philippe Armand
Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). However, the safety and efficacy of HSCT may be affected by prior PD-1 blockade. We conducted an international retrospective analysis of 39 patients with lymphoma who received prior treatment with a PD-1 inhibitor, at a median time of 62 days (7-260) before HSCT. After a median follow-up of 12 months, the 1-year cumulative incidences of grade 2-4 and grade 3-4 acute graft-versus-host disease (GVHD) were 44% and 23%, respectively, whereas the 1-year incidence of chronic GVHD was 41%. There were 4 treatment-related deaths (1 from hepatic sinusoidal obstruction syndrome, 3 from early acute GVHD). In addition, 7 patients developed a noninfectious febrile syndrome shortly after transplant requiring prolonged courses of steroids. One-year overall and progression-free survival rates were 89% (95% confidence interval [CI], 74-96) and 76% (95% CI, 56-87), respectively. One-year cumulative incidences of relapse and nonrelapse mortality were 14% (95% CI, 4-29) and 11% (95% CI, 3-23), respectively. Circulating lymphocyte subsets were analyzed in 17 patients. Compared with controls, patients previously treated with PD-1 blockade had significantly decreased PD-1+ T cells and decreased ratios of T-regulatory cells to conventional CD4 and CD8 T cells. In conclusion, HSCT after PD-1 blockade appears feasible with a low rate of relapse. However, there may be an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD-1 blockade. Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.

4 May 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CHCharles Herbaux
Charles Herbaux
JGJordan Gauthier
Jordan Gauthier
PBPauline Brice
Pauline Brice
EDElodie Drumez
Elodie Drumez
LYLoic Ysebaert
Loic Ysebaert
FMFranck Morschhauser
Franck Morschhauser
Key Points: PD-1 blockade with nivolumab provides durable disease control after allo-HCT. PD-1 blockade with nivolumab after allo-HCT is associated with 30% acute GVHD.

8 August 2017 in JAMA
Verified
Journal Article
Open access
PDF file
ABAnne Bergeron Bergeron
Anne Bergeron Bergeron
SCSylvie Chevret
Sylvie Chevret
AGAngela Granata
Angela Granata
PCPatrice Chevallier
Patrice Chevallier
LVLaure VINCENT
Laure VINCENT
FIfor the ALLOZITHRO Study Investigators
for the ALLOZITHRO Study Investigators
Importance Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post–lung transplant bronchiolitis obliterans syndrome. Objective To evaluate if the early administration of azithromycin can improve airflow decline–free survival after allogeneic HSCT. Design, Setting, and Participants The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers and involving participants who were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary function test results. Enrollment was from February 2014 to August 2015 with follow-up through April 26, 2017. Interventions Patients were randomly assigned to receive 3 times a week either 250 mg of azithromycin (n = 243) or placebo (n = 237) for 2 years, starting at the time of the conditioning regimen. Main Outcomes and Measures The primary efficacy end point was airflow decline–free survival at 2 years after randomization. Main secondary end points were overall survival and bronchiolitis obliterans syndrome at 2 years. Results Thirteen months after enrollment, the independent data and safety monitoring board detected an unanticipated imbalance across blinded groups in the number of hematological relapses, and the treatment was stopped December 26, 2016. Among 480 randomized participants, 465 (97%) were included in the modified intention-to-treat analysis (mean age, 52 [SD, 14] years; 75 women [35%]). At the time of data cutoff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 patients (30%) died (78 azithromycin vs 60 placebo). Two-year airflow decline–free survival was 32.8% (95% CI, 25.9%-41.7%) with azithromycin and 41.3% (95% CI, 34.1%-50.1%) with placebo (unadjusted hazard ratio [HR], 1.3; 95% CI, 1.02-1.70;P = .03). Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin group and 7 (3%) in the placebo group (P = .08). The azithromycin group had increased mortality, with a 2-year survival of 56.6% (95% CI, 50.2%-63.7%) vs 70.1% (95% CI, 64.2%-76.5%) in the placebo group (unadjusted HR, 1.5; 95% CI, 1.1-2.0;P = .02). In a post hoc analysis, the 2-year cumulative incidence of hematological relapse was 33.5% (95% CI, 27.3%-39.7%) with azithromycin vs 22.3% (95% CI, 16.4%-28.2%) with placebo (unadjusted cause-specific HR, 1.7; 95% CI, 1.2-2.4;P = .002). Conclusions and Relevance Among patients undergoing allogeneic HSCT for hematological malignancy, early administration of azithromycin resulted in worse airflow decline–free survival than did placebo; these findings are limited by early trial termination. The potential for harm related to relapse requires further investigation. Trial Registration clinicaltrials.gov Identifier:NCT01959100

1 April 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
EGElodie GAUTIER-VEYRET
Elodie GAUTIER-VEYRET
XFXavier Fonrose
Xavier Fonrose
JTJulia Tonini
Julia Tonini
ATAnne Thiebaut-Bertrand
Anne Thiebaut-Bertrand
MBMireille Bartoli
Mireille Bartoli
FSFrançoise Stanke-Labesque
Françoise Stanke-Labesque
Voriconazole (VRC) plasma trough concentrations ( C min ) are highly variable, and this could affect treatment efficacy and safety in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). We aimed to describe the intra- and interindividual variation of VRC C min throughout the course of VRC therapy and to identify the determinants of this variation. Clinical data, medications, and VRC C min ( n = 308) of 33 AHSCT patients were retrospectively collected. Cytochrome P450 (CYP450) genotypes of CYP2C19, CYP3A4, and CYP3A5 patients were retrospectively determined before allografting, and a combined genetic score was calculated for each patient. The higher the genetic score, the faster the metabolism of the patient. The VRC C min inter- and intraindividual coefficients of variation were 84% and 68%, respectively. The VRC dose ( D ) was correlated to VRC C min ( r = 0.412, P < 0.0001) only for oral administration. The administration route and the genetic score significantly affected the initial VRC C min . Considering oral therapy, patients with a genetic score of 2 ( P = 0.009). Subsequent VRC C min remained influenced by the genetic score ( P = 0.004) but were also affected by pump proton inhibitor comedication ( P < 0.0001). The high variability of VRC C min in AHSCT patients is partially explained by the route of administration, treatment with pump proton inhibitors, and the combined genetic score. This study suggests the interest in combined genetic score determination to individualize a priori the VRC dose and underlines the need for longitudinal therapeutic drug monitoring to adapt subsequent doses to maintain the VRC C min within the therapeutic range.

1 September 2014 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GDGandhi Damaj
Gandhi Damaj
MMMohammad Mohty
Mohammad Mohty
Marie RobinMarie Robin
Marie Robin
MMMauricette Michallet
Mauricette Michallet
PCPatrice Chevallier
Patrice Chevallier
IYIbrahim Yakoub-Agha
Ibrahim Yakoub-Agha
Cytoreduction before allogeneic stem cell transplantation (allo-SCT) for patients with myelodysplastic syndromes remains a debatable issue. After excluding patients who had received preconditioning induction chemotherapy, we analyzed 128 consecutive patients with myelodysplastic syndrome who received reduced-intensity or nonmyeloablative conditioning (RIC/NMA) allo-SCT. Among them, 40 received azacitidine (AZA) before transplant (AZA group) and 88 were transplanted up front (best supportive care [BSC] group). At diagnosis, 55 patients had intermediate 2 or high-risk scores per the International Prognostic Scoring System and 33 had a high cytogenetic risk score. Progression to a more advanced disease before allo-SCT was recorded in 22 patients. Source of stem cells were blood (n = 112) or marrow (n = 16) from sibling (n = 78) or HLA-matched unrelated (n = 50) donors. With a median follow-up of 60 months, 3-year overall survival, relapse-free survival, cumulative incidence of relapse, and nonrelapse mortality were, respectively, 53% versus 53% (P = .69), 37% versus 42% (P = .78), 35% versus 36% (P = .99), and 20% versus 23% (P = .74), for the AZA group and BSC group, respectively. Multivariate analysis confirmed the absence of statistical differences in outcome between the AZA and BSC groups, after adjusting for potential confounders using the propensity score approach. The absence of cytoreduction before RIC/NMA allo-SCT did not seem to alter the outcome. However, our results emphasize the need to perform prospective protocols to delineate the role of debulking strategy and to identify subsets of patients who may benefit from this approach.

10 October 2018 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EGElodie GAUTIER-VEYRET
Elodie GAUTIER-VEYRET
ATAurélie Truffot
Aurélie Truffot
Sébastien BaillySébastien Bailly
Sébastien Bailly
XFXavier Fonrose
Xavier Fonrose
ATAnne Thiebaut‐Bertrand
Anne Thiebaut‐Bertrand
FSFrançoise Stanke‐Labesque
Françoise Stanke‐Labesque